Business Context and Reporting Period
This Form 8-K is a current report filed by Tempest Therapeutics, Inc. on December 23, 2021, regarding an event that occurred on December 20, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol TPST.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of a member of the Board of Directors:
- Stella Xu notified the Board of her decision to resign, effective January 5, 2022.
- The resignation was explicitly stated as not being due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Investor Verification Checklist
- Confirm the effective date of Stella Xu's resignation (January 5, 2022).
- Verify if the Board has announced a replacement director to fill the vacancy.
- Review the Company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K does not include them.